LEIDEN, the Netherlands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR), today announced that it has entered into a research collaboration agreement with Galapagos N.V. (Euronext & NASDAQ:GLPG).
… R&D day Highlights Progress on Pipeline and Introduces Axiomer®, a novel proprietary RNA Technology Key program … the unmet need in DEB and the current treatment landscape. Axiomer®: ProQR will introduce its novel, proprietary RNA …
… ProQR Presents in vivo Proof of Concept Data for the Axiomer® RNA Editing Platform Technology Key updates ProQR … (Nasdaq:PRQR), today announced that a presentation titled “Axiomer ® Technology: Therapeutic Oligonucleotides for …
Today we are delighted to announce the further expansion of our collaboration with Lilly. Lilly is a leader in innovative RNA science, making them a great partner for our Axiomer technology.
… the event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial … and mentored over 50 Ph.D. and M.S. degree students. About Axiomer ® ProQR is pioneering a next-generation RNA base editing technology called Axiomer ® , which could potentially yield a new class of …
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
The presentation reviews EONs structure activity, the potential of the Axiomer platform as well as its applicability for the treatment of liver originated disorders. Presented at TIDES USA on May 9, 2023 by Gerard Platenburg - ProQR Therapeutics.
